Kallikreins

• 

  Subject Areas on Research

  • A kallikrein-targeting RNA aptamer inhibits the intrinsic pathway of coagulation and reduces bradykinin release. 
  • American Society of Clinical Oncology 2013 top five list in oncology. 
  • An overview of novel therapies for acute hereditary angioedema. 
  • Aprotinin improves functional outcome but not cerebral infarct size in an experimental model of stroke during cardiopulmonary bypass. 
  • Associations Between Prostate Volume and Oncologic Outcomes in Men Undergoing Focal Cryoablation of the Prostate. 
  • Characterization of inactive renin from human kidney and plasma. Evidence of a renal source of circulating inactive renin. 
  • Characterization of prorenin activation using a synthetic peptide substrate. 
  • Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. 
  • Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. 
  • Decreased kallikrein excretion in renal transplant treated with cyclosporine A. 
  • Disseminated intravascular coagulation: a reappraisal. 
  • Early results of prostate cancer radiation therapy: an analysis with emphasis on research strategies to improve treatment delivery and outcomes. 
  • Emerging applications of aptamers for anticoagulation and hemostasis. 
  • Exploring the Clinical Benefit of Docetaxel or Enzalutamide After Disease Progression During Abiraterone Acetate and Prednisone Treatment in Men With Metastatic Castration-Resistant Prostate Cancer. 
  • Hereditary angiodema: a current state-of-the-art review, VI: novel therapies for hereditary angioedema. 
  • Hierarchical Bayesian mixture modelling for antigen-specific T-cell subtyping in combinatorially encoded flow cytometry studies. 
  • Hormone naïve prostate cancer: predicting and maximizing response intervals. 
  • Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. 
  • Immune hemolytic transfusion reactions in monkeys: activation of the kallikrein system. 
  • Management of Postprostatectomy Biochemical Relapse With Salvage Radiotherapy: Results of an International Survey. 
  • Modulation of the BP response to diet by genes in the renin-angiotensin system and the adrenergic nervous system. 
  • New therapies for hereditary angioedema: disease outlook changes dramatically. 
  • Null association between vitamin D and PSA levels among black men in a vitamin D supplementation trial. 
  • Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. 
  • Pain, PSA flare, and bone scan response in a patient with metastatic castration-resistant prostate cancer treated with radium-223, a case report. 
  • Phase 2 Study of the Safety and Antitumor Activity of Apalutamide (ARN-509), a Potent Androgen Receptor Antagonist, in the High-risk Nonmetastatic Castration-resistant Prostate Cancer Cohort. 
  • Production and characterization of the monoclonal antibody against SGP120, a novel serum protein. 
  • Progesterone stimulates mitochondrial activity with subsequent inhibition of apoptosis in MCF-10A benign breast epithelial cells. 
  • Prostate epithelial cell of origin determines cancer differentiation state in an organoid transformation assay. 
  • Prostate-specific antigen response in black and white patients treated with abiraterone acetate for metastatic castrate-resistant prostate cancer. 
  • Prostate-specific antigen velocity: new methods, same results, still no evidence of clinical utility. 
  • Psychosocial trajectories of men monitoring prostate-specific antigen levels following surgery for prostate cancer. 
  • Radical prostatectomy versus radiation therapy: can pretreatment nomograms be used to select the appropriate prostate cancer treatment? 
  • Rising PSA Level in an Anxious Postprostatectomy Patient. 
  • Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial. 
  • Statin use and risk of prostate cancer and high-grade prostate cancer: results from the REDUCE study. 
  • Synergistic and tunable human gene activation by combinations of synthetic transcription factors. 
  • TET2 binds the androgen receptor and loss is associated with prostate cancer. 
  • The GNA13-RhoA signaling axis suppresses expression of tumor protective Kallikreins. 
  • The therapeutic potential of a kallikrein inhibitor for treating hereditary angioedema. 
  • Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. 
  • Tubular markers in renal transplant patients under cyclosporine. 
  • Urinary kallikrein in dogs with constriction of one renal artery. 
• 

  Keywords of People

  • Nielsen, Karen Cristina, Associate Professor of Anesthesiology, Anesthesiology, Ambulatory